Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada.


Journal

Obesity (Silver Spring, Md.)
ISSN: 1930-739X
Titre abrégé: Obesity (Silver Spring)
Pays: United States
ID NLM: 101264860

Informations de publication

Date de publication:
06 2019
Historique:
received: 05 12 2018
accepted: 21 02 2019
pubmed: 8 5 2019
medline: 12 3 2020
entrez: 8 5 2019
Statut: ppublish

Résumé

Real-world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. A cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was identified from six Canadian weight-management clinics. Post initiation values at 4 and 6 months were compared with baseline values using a paired t test. The full cohort consisted of 311 participants, with 210 in the ≥ 4-month persistence group and 167 in the ≥ 6-month persistence group. Average baseline BMI was 40.7 kg/m In a real-world setting, liraglutide 3.0 mg, when combined with diet and exercise, was associated with clinically meaningful weight loss.

Identifiants

pubmed: 31062937
doi: 10.1002/oby.22462
pmc: PMC6593982
doi:

Substances chimiques

Hypoglycemic Agents 0
Liraglutide 839I73S42A

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

917-924

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 The Authors. Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS).

Références

J Diabetes Sci Technol. 2015 Jul 16;10(1):164-74
pubmed: 26183599
Lancet Diabetes Endocrinol. 2014 Jun;2(6):474-80
pubmed: 24731674
QJM. 2006 Sep;99(9):565-79
pubmed: 16916862
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
Int J Obes (Lond). 2014 Jun;38(6):784-93
pubmed: 23999198
BMJ Open. 2012 May 11;2(3):
pubmed: 22581797
Diabetes Care. 2011 Jul;34(7):1481-6
pubmed: 21593294
Obesity (Silver Spring). 2019 Jan;27(1):7-9
pubmed: 30569641
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
J Health Psychol. 2013 Apr;18(4):574-86
pubmed: 22843633
Lancet. 2009 Mar 28;373(9669):1083-96
pubmed: 19299006
CMAJ. 2007 Apr 10;176(8):S1-13
pubmed: 17420481
Am J Clin Nutr. 2001 Nov;74(5):579-84
pubmed: 11684524
J Am Coll Nutr. 2009 Apr;28(2):159-68
pubmed: 19828901
Am J Clin Nutr. 1992 Aug;56(2):320-8
pubmed: 1386186
Can J Surg. 2012 Aug;55(4):239-43
pubmed: 22617538
Int J Behav Med. 2010 Sep;17(3):176-81
pubmed: 20033629
Int J Obes (Lond). 2008 Sep;32(9):1431-7
pubmed: 18607383
Health Rep. 2006 Aug;17(3):9-25
pubmed: 16981483
BMC Obes. 2016 Mar 09;3:14
pubmed: 26966544
Int J Obes (Lond). 2006 Jul;30(7):1132-7
pubmed: 16432536
Endocr Pract. 2012 Sep-Oct;18(5):642-8
pubmed: 23047927
Obes Rev. 2014 Mar;15(3):169-82
pubmed: 24118750
Clin Pharmacol Ther. 2016 Aug;100(2):147-59
pubmed: 26916672
J Clin Endocrinol Metab. 2015 Feb;100(2):342-62
pubmed: 25590212
Int J Clin Pract Suppl. 2010 Oct;(167):4-11
pubmed: 20887299
Obes Res. 2003 Jul;11(7):888-94
pubmed: 12855759

Auteurs

Sean Wharton (S)

Wharton Medical Clinic, Burlington, Canada.

Aiden Liu (A)

Novo Nordisk Canada Inc., Mississauga, Canada.

Arash Pakseresht (A)

Novo Nordisk Canada Inc., Mississauga, Canada.

Emil Nørtoft (E)

Novo Nordisk A/S, Søborg, Denmark.

Christiane L Haase (CL)

Novo Nordisk A/S, Søborg, Denmark.

Johanna Mancini (J)

IQVIA, Kirkland, Canada.

G Sarah Power (GS)

IQVIA, Mississauga, Canada.

Sarah Vanderlelie (S)

Wharton Medical Clinic, Burlington, Canada.

Rebecca A G Christensen (RAG)

Wharton Medical Clinic, Burlington, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH